0000000001302041
AUTHOR
G.j. Kahaly
The eye in thyroid autoimmunity – Autoimmunité et œil lors de la maladie de Basedow
Thyroid eye disease or thyroid-associated orbitopathy (TAO) is the commonest cause of orbital disease with an inflammatory component. With a basic knowledge of both orbital anatomy and the pathogenesis of TAO, it is easy to understand how its typical constellation of features originates. These features can be considered as primary or secondary. Primary features are those due directly to the disease process affecting a tissue e.g. restrictive myopathy. Secondary features occur due to the interaction of the affected tissue and the anatomical configuration of the tissues e.g. corneal ulceration or optic neuropathy, and are less likely to be florid at presentation. TAO is characterized by an im…
Supplementary Material for: Comparison of a Novel Homogeneous Cyclic Amp Assay and a Luciferase Assay for Measuring Stimulating Thyrotropin-Receptor Autoantibodies
Objective: Stimulating thyrotropin-receptor antibodies (TSAb) cause Graves’ disease (GD). We tested a novel homogeneous fluorescent 3′,5′ cyclic adenine monophosphate (cAMP) assay for the detection of TSAb in a bioassay. Methods: Chinese hamster ovary (CHO) cell lines expressing either a chimeric (MC4) or wild-type (WT) TSH-R were incubated with the adenyl cyclase activator forskolin, a human TSAb monoclonal antibody (M22), and with sera from GD patients. Intracellular cAMP levels were measured using a Bridge-It® cAMP assay, and the results were compared with a luciferase-based bioassay. Results: Both cell lines were stimulated with forskolin concentrations (0.006–200 µM) in a dose-dependen…
Supplementary Material for: Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves’ Orbitopathy: A Prospective Trial
Objectives: To investigate the predictive factors for changes in the quality of life (GO-QoL) of patients with Graves’ orbitopathy (GO) prior to and after specific treatment. Methods: A prospective follow-up study was conducted at an academic tertiary referral orbital center with a joint thyroid-eye clinic on 100 consecutive patients with GO. Before and after the standard 12-week course of weekly intravenous methylprednisolone (cumulative dose 4.5 g), the GO-QoL questionnaire provided by the European Group on Graves’ Orbitopathy (EUGOGO) was completed. Endocrine and ophthalmic assessments were performed at each visit. Results: All patients were biochemically euthyroid and untreated for GO a…